Form 4: Ionis Pharmaceuticals EVP Joseph Baroldi Sells Shares

EVP and Chief Business Officer Joseph Baroldi sold 1,626 shares of Ionis Pharmaceuticals common stock via a 10b5-1 plan.

Summary

• Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, sold 1,626 shares of common stock.
• The shares were sold at a weighted average price of $71.7877 per share.
• The transaction occurred on April 28, 2026.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025.
• Following the transaction, the reporting person maintains direct ownership of 44,909 shares and indirect ownership of 4,347 shares held by his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance activities and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is the industry standard for corporate executives to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-planned 10b5-1 arrangement.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Sale, Biotech